Read this company snapshot
Daily valuation snapshot
Genmab A/S ADS: source evidence dated 2026-10-09.
- Daily close (USD)
- $37.07
- Market capitalization (USD)
- $2,381,317,784.56
- Price / earnings (TTM)
- 2.47
- Price / book
- 0.41
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research GMAB in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research GMAB in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing GMAB with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $37.07 |
| Market capitalization (USD) | $2,381,317,784.56 |
| Price / earnings (TTM) | 2.47 |
| Price / book | 0.41 |
No matching rows. Clear the filter to see all records.
Read GMAB's valuation metrics
Company size
Genmab A/S ADS's recorded market capitalization is $2,381,317,784.56. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
GMAB's recorded P/E is 2.47: about $2.47 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
GMAB's recorded price-to-book ratio is 0.41. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Genmab A/S ADS with Aurora
Use the snapshot above to ask a specific question about GMAB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow GMAB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.